Pharmaceutical Industry Gifts Associated With Inappropriate Prescribing and Higher Costs, Cochrane Review Finds
Gifts and payments from pharmaceutical companies to clinicians are associated with inappropriate prescribing, an increase in prescription volume, and higher overall costs, according to a Cochrane review published on October 9, 2026. The systematic review, which analyzed 93 studies covering millions of prescribers, provides the first gold-standard global assessment of how marketing interactions shape clinical decision-making.
While pharmaceutical companies argue that promotional activities and professional education help healthcare professionals learn about new treatments, the review found that even minor gifts, such as food and drink, foster an unconscious sense of obligation that alters prescribing habits. The findings highlight a stark contrast between regulatory approaches in the United States, which utilizes extensive public disclosure data, and the United Kingdom, which relies primarily on voluntary self-regulation.
Analysis of 93 Global Studies Reveals Widespread Marketing Influence
The Cochrane review evaluated 93 studies examining pharmaceutical promotional behaviors, including advertising, educational events, free drug samples, gifts, payments, and conflict-of-interest policies. Of these studies, 82 were conducted in the United States, while 11 took place in the European Union or the UK.
Out of 62 studies investigating gifts and payments—which included consultancy fees, travel expenses, conference funding, and food—10 studies covering 2.9 million prescribers demonstrated a direct link to decreased prescribing appropriateness compared to receiving fewer or no gifts. Furthermore, 39 studies involving 3.9 million prescribers found evidence of an increased quantity of prescriptions written. An additional 25 studies covering 2.5 million prescribers linked these payments to higher prescription costs.
Lead author Barbara Mintzes, a professor in pharmacy at the University of Sydney, noted that clinicians frequently underestimate how marketing affects their judgment. “Doctors often think that … they can’t be bought for the price of a sandwich but the data shows this is an effective marketing strategy,” Mintzes stated, according to The Sydney Morning Herald. University of Queensland General Practitioner and co-author Geoff Spurling added that marketing tactics are pervasive globally, noting that even low-cost meals valued around $13 influence prescribing habits.
Contrasting Regulatory Frameworks in the UK and the United States
The availability of granular data largely dictates where research is conducted. Because the United States requires pharmaceutical companies to publicly report all payments to prescribers, researchers can easily compare industry transactions with individual prescribing records. By contrast, the UK lacks this level of transparency.
Piotr Ozieranski, a reader at the Department of Social and Policy Sciences at the University of Bath, pointed out that the UK relies on a voluntary system of self-regulation that allows companies to manage their own disclosures. Ozieranski cautioned that the scarcity of UK-based studies in the review does not mean industry payments have no effect on British prescribing habits. He criticized upcoming UK government guidance on drug company payment disclosures for failing to establish a robust data infrastructure similar to the US system, stating, “You can’t regulate what you can’t see.”
Meanwhile, Amit Aggarwal, medical director for the Association of the British Pharmaceutical Industry (ABPI), defended current industry practices in the UK. Aggarwal stated that company marketing must adhere to the ABPI’s strict code of practice, which prohibits gifts and subjects hospitality to rigorous reporting standards. He also pointed to ABPI-commissioned research from 2024 showing that hospitals engaging in industry partnerships are up to two-and-a-half times more likely to closely follow National Institute for Health and Care Excellence (NICE) guidelines, leading to better-controlled conditions for patients.
Common Questions Regarding Industry Payments and Prescribing
* What specific types of gifts and payments were examined in the Cochrane review?
The review analyzed consultancy payments, travel expenses, conference and educational costs, and food and drink provided by pharmaceutical companies to clinicians.
* Why were no UK studies included in the analysis of gifts and prescribing appropriateness?
Out of the 62 studies examining gifts, payments, and prescribing appropriateness, none originated from the UK due to a lack of granular, publicly accessible disclosure data.
* What intervention do the review authors recommend to mitigate these impacts?
The authors emphasized the importance of strict conflict-of-interest policies during professional education and in clinical practice to reduce clinician exposure to promotional interactions.